Aztreonam
Aztreonam structure
|
Common Name | Aztreonam | ||
|---|---|---|---|---|
| CAS Number | 78110-38-0 | Molecular Weight | 435.433 | |
| Density | 1.83 | Boiling Point | N/A | |
| Molecular Formula | C13H17N5O8S2 | Melting Point | 227°C | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins.
J. Allergy Clin. Immunol. 135(4) , 972-6, (2015) Studies performed on samples larger than 100 subjects with a documented IgE-mediated hypersensitivity to penicillins have demonstrated a cross-reactivity rate of approximately 1% between penicillins and both imipenem and meropenem, whereas a single study foun... |
|
|
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Antimicrob. Agents Chemother. 59(1) , 467-74, (2014) AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and... |
|
|
An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.
Antimicrob. Agents Chemother. 58(12) , 7225-33, (2014) Nitrofurantoin has been used for decades for the treatment of urinary tract infections (UTIs), but clinically significant resistance in Escherichia coli is uncommon. Nitrofurantoin concentrations in the gastrointestinal tract tend to be low, which might facil... |
|
|
LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus.
Antimicrob. Agents Chemother. 59(1) , 145-51, (2014) Nasal decolonization has a proven effect on the prevention of severe Staphylococcus aureus infections and the control of methicillin-resistant S. aureus (MRSA). However, rising rates of resistance to antibiotics highlight the need for new substances for nasal... |
|
|
An outbreak of blaOXA-51-like- and blaOXA-66-positive Acinetobacter baumannii ST208 in the emergency intensive care unit.
J. Med. Microbiol. 63(Pt 11) , 1517-23, (2014) A series of clinical isolates of drug-resistant (DR) Acinetobacter baumannii with diverse drug susceptibility was detected from eight patients in the emergency intensive care unit of Tokai University Hospital. The initial isolate was obtained in March 2010 (A... |
|
|
Effects of electron beam irradiation on the migration of antioxidants and their degradation products from commercial polypropylene into food simulating liquids.
Wiad. Lek. 46(1-2) , 56-61, (1993) The influence of electron beam irradiation on migrational behaviour of additives present in food packaging material was studied. The migration experiments were carried out on irradiated and non-irradiated polypropylene pouches containing aqueous food simulati... |
|
|
Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores.
Thorax 70(1) , 12-20, (2015) The Quality of Life-Bronchiectasis (QOL-B), a self-administered, patient-reported outcome measure assessing symptoms, functioning and health-related quality of life for patients with non-cystic fibrosis (CF) bronchiectasis, contains 37 items on 8 scales (Resp... |
|
|
[Revival of selected well-tried antibiotics. Special features of the antiinfective agents penicillin G, fosfomycin, aztreonam and colistin].
Med. Monatsschr. Pharm. 35(10) , 367-77, (2012) Although a worldwide increasing incidence of bacterial infections with panresistant pathogens may need innovative antiinfective agents, no breakthrough developments can be expected in the near future. As a consequence, well-tried antibiotics like aztreonam, f... |
|
|
Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.
Expert Rev. Respir. Med. 4(4) , 435-44, (2010) Acquisition of Pseudomonas aeruginosa, the most prevalent organism isolated from cystic fibrosis (CF) airways, is associated with an accelerated clinical deterioration and reduced survival. Strategies to chronically suppress P. aeruginosa infections in indivi... |
|
|
Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient.
Am. J. Surg. 179(2A Suppl) , 45S-50S, (2000) In 1995 the American Thoracic Society issued an official consensus statement on the treatment of hospital-acquired pneumonia (HAP). Classes of antimicrobials included in the list of antimicrobials deemed to be suitable for the empiric treatment of severe HAP ... |